Good news for OncoBEAM liquid biopsy
November 2017

HAMBURG, Germany—New data is available from Sysmex Inostics, a subsidiary of Sysmex Corp., regarding a real-world prospective evaluation of its OncoBEAM RAS CRC test for routine clinical use in hospital laboratories. The comprehensive blood-based test assesses 34 mutations in KRAS and NRAS (RAS) to determine RAS mutation status in patients with metastatic colorectal cancer before they begin treatment. The test's liquid biopsy testing was compared with tissue testing in more than 230 patients, and the overall concordance of results from plasma and tissue RAS mutation testing was 90.5 percent, with positive percent agreement of 86.9 percent and negative percent agreement of 95.1 percent. A Sysmex press release noted that “a high overall agreement was observed between results obtained from plasma and tissue samples” and that “these findings indicate that plasma OncoBEAM RAS testing is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.